Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides

Prostate

Volumn 68, Issue 8, 2008, Pages 809-819

  Wang, Wei ^a   Rayburn, Elizabeth R ^a   Hao, Miao ^b   Zhao, Yuqing ^a,c   Hill, Donald L ^a   Zhang, Ruiwen ^a   Wang, Hui ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Chemotherapy; Ginsenosides; Radiotherapy

Indexed keywords

25 HYDROXYPROTOPANAXADIOL; 25 HYDROXYPROTOPANAXATRIOL; ANTINEOPLASTIC AGENT; CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DOCETAXEL; GEMCITABINE; GINSENOSIDE; NATURAL PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; EXPERIMENTAL THERAPY; HOST; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TOXICITY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FIBROBLASTS; G1 PHASE; GINSENOSIDES; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 45349085085     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20742     Document Type: Article

References (40)

1. Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 2004;9:259-274.
2. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: Multiple constituents and multiple actions. Biochem Pharmacol 1999;58: 685-1693.
3. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, Pugh W, Rue PA, Polonsky KS, Yuan CS. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 2002;51:1851-1858.
4. Li TSC. Asian and American ginseng: A review. HortTechnology 1995;5:27-34.
5. Kitts DD, Hu C. Efficacy and safety of ginseng. Public Health Nutr 2000;4:473-485.
6. Kitts DD, Wijewickreme AN, Hu C. Antioxidant properties of North American ginseng extract. Mol Cell Biochem 2000;203: 1-10.
7. Hasegawa H, Uchiyama M. Antimetastatic efficacy of orally administered ginsenoside Rb1 in dependence on intestinal bacterial hydrolyzing potential and significance of treatment with an active bacterial metabolite. Planta Med 1998;64:696-700.
8. Wakabayashi C, Hasegawa H, Murata J, Saiki I. In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Oncol Res 1997;9:411-417.
9. Sato K, Mochizuki M, Saiki I, Yoo YC, Samukawa K, Azuma I. Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biol Pharmaceut Bull 1994;17: 635-639.
10. Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, Kudoh K, Nagata I, Shinomiya N. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res 1998;98:733-740.
11. Popovich DG, Kitts DD. Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch Biochem Biophys 2002;406:1-8.
12. Odashima S, Ohta T, Kohno H, Matsuda T, Kitagawa I, Abe H, Arichi S. Control of phenotypic expression of cultured B16 melanoma cells by plant glycosides. Cancer Res 1985;45:2781-2784.
13. American Cancer Society, Inc. Leading, Sites of New Cancer Cases and Deaths-2007 Estimates. Surveillance Research. 2007. Available online: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf.
14. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-887.
15. Petrylak DP. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 2005;65:3-7.
16. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004;92:287-295.
17. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 2006;59:589-601.
18. 3-PPD], a novel natural product from Panax notoginseng. Med Chem 2006;3:51-60.
19. Zhao YQ, Yuan CL, Fu YQ, Wei XJ, Zhu HJ, Chen YJ, Wu LJ, Li X. Chemical studies of minor triterpene compounds isolated from the stems and leaves of Panax ginseng CA Meyer. Yao Xue Xue Bao 1990;25:297-301.
20. Zhang Z, Li M, Wang H, Agrawal S, Chen X, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003;100:11636-11641.
21. Qian T, Cai Z, Wong RN, Jiang ZH. Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Commun Mass Spectrom 2005;19:3549-3554.
22. Qian T, Cai Z, Wong RN, Mak NK, Jiang ZH. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B Analyt Technol Biomed Life Sci 2005;816:223-232.
23. Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 2003;84:187-192.
24. Rhee YH, Ahn JH, Choe J, Kang KW, Joe C. Inhibition of mutagenesis and transformation by root extracts of Panax ginseng in vitro. Planta Med 1991;57:125-128.
25. Ota T, Fujikawa-Yamamoto K, Zong ZP, Yamazaki M, Odashima S, Kitagawa I, Abe H, Arichi S. Plant-glycoside modulation of cell surface related to control of differentiation in cultured B16 melanoma cells. Cancer Res 1987;47:3863-3867.
26. Lee SJ, Ko WG, Kim JH, Sung JH, Moon CK, Lee BH. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem Pharmacol 2000;60:677-685.
27. Kim JY, Germolec DR, Luster MI. Panax ginseng as a potential immunomodulator: Studies in mice. Immonopharmacol Immunotoxicol 1990;12:257-276.
28. Schafer KA. The cell cycle: A review. Vet Pathol 1998;35:461-478.
29. Seville LL, Shah N, Westwell AD, Chan WC. Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets 2005;5:159-170.
30. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006;13:1351-1359.
31. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 Years and counting. Curr Cancer Drug Targets 2005;5:3-8.
32. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 2004;279:16000-16006.
33. Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005;24:7238-7247.
34. Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: In vitro and in vivo activities and mechanisms. Ann NY Acad Sci 2003;1002:217-235.
35. Zhang Z, Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 2005;5:9-20.
36. Bae EA, Shin JE, Kim DH. Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol Pharm Bull 2005;28:1903-1908.
37. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology; Prostate Cancer Version 2 2005. NCCN 2006.
38. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001;16:S28-37.
39. Chang YS, Seo EK, Gyllenhaal C, Block KI. Panax ginseng: A role in cancer therapy? Integr Cancer Ther 2003;2:13-33.
40. Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, Im DS. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 2004;27:429-435.